CAR T-Cell Therapy Shows Promise for Treating Lupus

A new study shows a type of cellular therapy originally developed to treat cancer, CAR T-cell therapy, is showing promise as a potential treatment for people with difficult-to-treat lupus.
Study Shows How Melanoma Resists Drugs and Immune Defenses

A new study shows melanoma forms resistance against the MAPK inhibitors that are commonly used to treat it, while at the same time actively suppressing the immune cells that would otherwise help eliminate it.
mRNA Vaccine Reduces Risk of Melanoma Recurrence or Death

New clinical trial results show a personalized mRNA-based melanoma vaccine, intismeran, significantly reduces the risk of cancer recurrence or death within two years.
COVID-19 Vaccine Generates Immune Response in Adolescents

A new Phase II clinical trial shows HIPRA’s COVID-19 vaccine, BIMERVAX, administered as a booster dose after two previous doses with Comirnaty (Pfizer/BNTech), induces a broad immune response against multiple SARS-CoV-2 variants in adolescents.
Women More Likely Than Males to Have Autoimmune Disease Misdiagnosed as Psychosomatic Condition

A study has found females with autoimmune diseases are significantly more likely than males to have their autoimmune disease misdiagnosed as a psychiatric or psychosomatic condition.
Early IVIG Reduces Infections in Transplant Patients

A clinical trial at the Universidad Autónoma de Madrid (UAM) suggests that early administration of intravenous immune globulin (IVIG) could decrease the occurrence of new infections in transplanted individuals who present with hypogammaglobulinemia.
FDA Approves atezolizumab to Treat dMMR Colon Cancer

The Food and Drug Administration has approved atezolizumab in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III mismatch repair deficient colon cancer
FDA Approves IMAAVY to Treat Warm Autoimmune Hemolytic Anemia

The U.S. Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening autoantibody disease, in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. The approval, which follows FDA priority review, marks the first time a therapy was proven […]
FDA Approves Elecsys pTau217 to Identify Alzheimer’s in Individuals 55 Years and Older

The U.S. Food and Drug Administration (FDA) has cleared the Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test, providing clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer’s disease in individuals 55 years and older with signs, symptoms or complaints of cognitive decline. Developed in […]
Gamgertamig Is Approved by FDA to Treat Pemphigus
Lakefront’s Gamgertamig has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) to treat pemphigus. The drug is being developed by Lakefront in collaboration with Gilead Sciences. Ongoing clinical trials in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027. These include: A Phase […]